awechalekar
@awechalekar
Followers
1K
Following
3K
Media
168
Statuses
1K
Professor of Medicine and Haematology; UCL; UCLH; Royal Free London
United Kingdom
Joined January 2018
@awechalekar highlighting that hematologic response criteria needs to evolve in AL amyloidosis with the arrival of BsAbs. Patients might not achieve traditional aCR for months due to persistent IFE and/or abnormal ratio despite complete elimination of FLCs. #AmyloidosisForum
0
2
13
Exciting opportunity to work with our team at the National Amyloidosis Centre and @UCLH Amyloidosis MGCS clinic for haematology trainees interested in plasma cell disorders @UKMyelomaSoc @BritSocHaem - DM me if interested details at NHS jobs
0
6
19
Excellent work by @Chf1992 and colleagues on this under-reported area in #cardiooncology @awechalekar @ICOSociety @BritishCardioSo
It is also a great honour to see our work discussed in the excellent @EHJCVIEiC editorial by @benayozbay and @SadeLeylaElif🔗 https://t.co/BVaLQzCGz1 Thank you for this outstanding contribution to the discussion! 🙏 @arjunkg @Javihf_10 @keramidakallio3 @pedroluisSF @anguita_m
0
4
8
It is also a great honour to see our work discussed in the excellent @EHJCVIEiC editorial by @benayozbay and @SadeLeylaElif🔗 https://t.co/BVaLQzCGz1 Thank you for this outstanding contribution to the discussion! 🙏 @arjunkg @Javihf_10 @keramidakallio3 @pedroluisSF @anguita_m
academic.oup.com
This editorial refers to ‘Prognostic value of right ventricular longitudinal strain assessed by multimodal imaging in amyloidosis: systematic review and me
Team science at its best! 💪 So proud to share this comprehensive meta-analysis on the prognostic value of RV strain in #amyloidosis 📈 asssesed by multimodal imaging (echo/CMR). Honored as last author—thanks for the spotlight! https://t.co/UGSvh1bBY5
@EACVIPresident @EHJCVIEiC
1
10
16
A shout out to clinical problem solving @NEJM by Dr Mihir Wechalekar and colleagues - A Shifting Frame | New England Journal of Medicine
nejm.org
A 32-year-old asymptomatic woman was found in early pregnancy to have abnormal liver-enzyme levels, with similar results on repeat testing. Levels of bilirubin, γ-glutamyltransferase, and alkaline ...
0
1
4
3 Pillars of AL treatment 1. Plasma cell therapy 2. FLC stabilizer 3. Amyloid fibrils depleter So far only #1 is currently approved and widely used. Few depleters did not meet their primary endpoint. Hopefully Anselimamab shows promising response.
0
4
15
Reunion international sobre gammapatias monoclonales y riñon IKGM group. Excelentes conferencias y debates en 2 días de reunion! Mención especial y emotivo recuerdo al Dr Frank Bridoux
0
5
18
Renal Transplant in myeloma- current perspective at #IKMG 2025 from @Heather Landau risk stratified selection of patients for renal transplant in myeloma with renal failure @IMFmyeloma @Myeloma_Society
1
4
24
Massive cyber security attacks in European airports. Arrived 3 hours early at Heathrow and I’m still in line. They’re checking people in with pen and paper. Flight’s already delayed, tons of cancellations.
1
2
10
22nd Annual meeting of @Myeloma_Society #IMS25 We are honoring two pioneers at the opening. The first is Dr. Jean Paul Fermand. The first to test early vs late transplant in myeloma. And proposed the concept of monoclonal gammopathy of clinical significance.
0
6
24
We are honoring Dr. Bruce Cheson today with the Mayo Clinic Kyle Lifetime Achievement Award. Dr. Cheson helped me greatly in my career. We visited with Dr. Kyle who is 97. Heard remarkable stories about hematology.
7
13
104
Isatuximab for Relapsed and/or Refractory AL Amyloidosis: Results of a Prospective Phase 2 Trial (SWOG S1702)
ashpublications.org
Key Points. Isatuximab in relapsed and/or refractory AL amyloidosis resulted in an overall hematologic response rate of 77%.The high rates of hematologic r
0
8
25
Very nice work by @DrGarethMorgan1 multiomic analysis of Waldenström macroglobulinemia defines distinct disease subtypes - a b cell and pc cell phenotype.
ashpublications.org
Key PointsSingle-cell multiome analysis identifies 2 subtypes of WM with variable differentiation capacity, and SPI1, SPIB, and XBP1 activity.The MBC-like
0
0
4
Great evening out with Julia Neuberger and @probert_david Co-presenting awards to some of the amazing people who work at @uclh … very special people doing very special things in a very special NHS.
24
9
184
A great honor to received this distinguished from @ASNC and its president @PanithayaC Happy to be a new #ASNC2025 “fellow”
1
3
12
A busy #amyloidosis session #ASNC2025 Dr. Rafael Lopez covered important issues with mishandling of amyloid imaging #cardiotwitter
0
6
15
CONGRESS | #SOHO2025 | PRESENTATION Sagar Lonial @SagarLonialMD @WinshipAtEmory delivered the plenary talk on #MultipleMyeloma, emphasizing a path toward potential cure; highlighted deep, durable responses with fixed-duration regimens, adaptive strategies beyond resistance,
2
7
19
Interesting to see digitalis return to heart failure world - Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction - anecdotally used with benefit in advanced AL with poor EF
nejm.org
The therapeutic efficacy of the cardiac glycoside digitoxin in patients with heart failure and reduced ejection fraction is not established. In this international, double-blind, placebo-controlled ...
0
3
10